Sven-Eric Bursell

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE To assess ocular and systemic safety and pharmacodynamic effects of the oral PKC beta selective inhibitor ruboxistaurin (RBX; LY333531) mesylate in patients with diabetes. METHODS This was a double-masked, placebo-controlled, parallel, randomized, single-center clinical study evaluating the effect of oral administration of RBX (8 mg twice a day,(More)
  • 1